Rikio Suzuki

Dr. Rikio Suzuki

Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Rikio SuzukiRikio Suzuki
Rikio Suzuki
DODaisuke Ogiya
Daisuke Ogiya
YOYoshiaki Ogawa
Yoshiaki Ogawa
HKHiroshi Kawada
Hiroshi Kawada
KAKiyoshi Ando
Kiyoshi Ando
The prognosis of patients with multiple myeloma (MM) has improved dramatically with the introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant, following an intractable and incurable course. A myeloma niche (MM niche) develops in the bone marrow microenvironment and plays an important role in the drug resistance mechanism of MM. In particular, adhesion between MM cells and bone marrow stromal cells mediated by adhesion molecules induces cell adhesion-mediated drug resistance (CAM-DR). Analyses of the role of mitochondria in cancer cells, including MM cells, has revealed that the mechanism leading to drug resistance involves exchange of mitochondria between cells (mitochondrial transfer) via tunneling nanotubes (TNTs) within the MM niche. Here, we describe the discovery of these drug resistance mechanisms and the identification of promising therapeutic agents primarily targeting CAM-DR, mitochondrial transfer, and TNTs.

1 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ATAkihiro Takeshita
Akihiro Takeshita
NANorio Asou
Norio Asou
YAYoshiko Atsuta
Yoshiko Atsuta
HFHiroaki Furumaki
Hiroaki Furumaki
TSToru Sakura
Toru Sakura
TGthe Japan Adult Leukemia Study Group
the Japan Adult Leukemia Study Group
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance of other important prognostic factors was evaluated with multivariate analyses. Patients and Methods: Newly diagnosed acute promyelocytic leukemia (APL) patients were registered with the study. Induction was composed of ATRA and chemotherapy. Patients who achieved molecular remission after consolidation were randomly assigned to maintenance with tamibarotene or ATRA. Results: Of the 344 eligible patients, 319 (93%) achieved complete remission (CR). After completing consolidation, 269 patients underwent maintenance random assignment—135 to ATRA, and 134 to tamibarotene. By multivariate analysis, overexpression of CD56 in blast was an independent unfavorable prognostic factor for relapse-free survival (RFS) (p = 0.006) together with more than 10.0 × 109/L WBC counts (p = 0.001) and the ATRA arm in maintenance (p = 0.028). Of all phenotypes, CD56 was related most clearly to an unfavorable prognosis. The CR rate, mortality rate during induction and overall survival of CD56+ APL were not significantly different compared with CD56− APL. CD56 is continuously an independent unfavorable prognostic factor for RFS in APL patients treated with ATRA and chemotherapy followed by ATRA or tamibarotene maintenance therapy.

3 November 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
Rikio SuzukiRikio Suzuki
Rikio Suzuki
YKYuka Kitamura
Yuka Kitamura
YNYoshihiko Nakamura
Yoshihiko Nakamura
HAHibiki Akashi
Hibiki Akashi
YOYoshiaki Ogawa
Yoshiaki Ogawa
KAKiyoshi Ando
Kiyoshi Ando
Https://doi.org/10.18632/oncotarget.27775 Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

24 October 2024 in Blood Neoplasia
Verified
Journal Article
Open access
TJTomoyasu Jo
Tomoyasu Jo
KYKyoko Yoshihara
Kyoko Yoshihara
MRMasaki Ri
Masaki Ri
NTNobuhiro Tsukada
Nobuhiro Tsukada
NMNaoya Mimura
Naoya Mimura
YAYasuyuki Arai
Yasuyuki Arai
• Low platelet counts and low CD4/CD8 T-cell ratios at apheresis increase the risk of CAR T-cell manufacturing failure in multiple myeloma. • Alkylating agents within 6 months before apheresis were associated with decreased platelet counts and CD4/CD8 ratios at apheresis.

29 October 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
DODaisuke Ogiya
Daisuke Ogiya
Rikio SuzukiRikio Suzuki
Rikio Suzuki
SGShun Goto
Shun Goto
YNYosuke Nakagawa
Yosuke Nakagawa
MNMiina Nasukawa
Miina Nasukawa
HKHiroshi Kawada
Hiroshi Kawada
Recent advances in multiple myeloma (MM) treatment, including bispecific antibodies (BsAbs), have improved outcomes. Elranatamab, a BsAb targeting B-cell maturation antigen and CD3, has shown efficacy in relapsed/refractory MM (RRMM). However, its use in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) is not well documented, as clinical trials often exclude this population. We report a 72-year-old woman with RRMM and ESRD on HD who was successfully treated with elranatamab after multiple prior therapies. She achieved a stringent complete response with undetectable minimal residual disease. Adverse events included grade 1 cytokine release syndrome, mild hypotension, and acute cholangitis, all resolved with appropriate management. Our literature review suggests BsAbs can be effective and generally well-tolerated in RRMM patients with ESRD on HD, although infection risk warrants caution. This report highlights elranatamab as a promising option for this vulnerable population. While initial responses and safety appear favourable, further studies are required to establish long-term outcomes.

11 April 2024 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
TSToshiro Seki
Toshiro Seki
Rikio SuzukiRikio Suzuki
Rikio Suzuki
SOShino Ohshima
Shino Ohshima
YMYoshiyuki Manabe
Yoshiyuki Manabe
SOShion Onoue
Shion Onoue
YKYoshie Kametani
Yoshie Kametani
Progesterone suppresses several ancient pathways in a concentration-dependent manner. Based on these characteristics, progesterone is considered a candidate anticancer drug. However, the concentration of progesterone used for therapy should be higher than the physiological concentration, which makes it difficult to develop progesterone-based anticancer drugs. We previously developed liposome-encapsulated progesterone (Lipo-P4) with enhanced anticancer effects, which strongly suppressed triple-negative breast cancer cell proliferation in humanized mice. In this study, we aimed to clarify whether Lipo-P4 effectively suppresses the proliferation of Blineage cancer cells. We selected six B-cell lymphoma and two myeloma cell lines, and analyzed their surface markers using flow cytometry. Next, we prepared liposome-encapsulated progesterone and examined its effect on cell proliferation in these B-lineage cancer cells, three ovarian clear cell carcinoma cell lines, two prostate carcinoma cell lines, and one triple-negative breast cancer adenocarcinoma cell line. Lipo-P4 suppressed the proliferation of all cancer cell lines. All B-lineage cell lines, except for the HT line, were more susceptible than the other cell types, regardless of the expression of differentiation markers. Empty liposomes did not suppress cell proliferation. These results suggest that progesterone encapsulated in liposomes efficiently inhibits the proliferation of B-lineage cells and may become an anticancer drug candidate for B-lineage cancers.